Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

For locally advanced rectal cancer, would you consider utilizing the RAPIDO trial approach of short course radiation followed by neoadjuvant chemotherapy prior to surgery?

7
5 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic

RAPIDO trial is an important study since it is the first phase III study that reported final results of a total neoadjuvant treatment (TNT) approach for rectal cancer.The RAPIDO study is a European study and we need to be aware of the practice difference (in the US, we traditionally use neoadjuvant ...

Would you offer adjuvant avapritinib or imatinib for a high-risk, PDGFR D842V-mutated GIST after resection?

1

When would you consider fulvestrant + alpelisib in a postmenopausal patient who has HR+, PIK3CA mutant, metastatic breast cancer instead of initial CDK4/6 inhibitor therapy?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Ohio State University

Given that SOLAR-1 study enrolled patients who previously progressed after at least 1 line of endocrine therapy for metastatic disease, I would not offer alpelisib as front line therapy. My preference for front line therapy for metastatic, HR+, PIK3CA mutation-positive breast cancer is a combination...

Do you offer local treatment to the breast primary in patients with de novo oligometastatic hormone positive breast cancer?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of North Carolina at Chapel Hill

The E2108 study by Khan et al., showed that early local therapy in de-novo metastatic BC did not improve PFS/OS, and in fact showed worse OS in the small subset of TNBC in the study (20 patients). Although there was improved locoregional control in the local therapy arm, there was no quality of life...

How would you treat a young patient with symptomatic Rosai-Dorfman disease who has recurrent, life-threatening pericardial and pleural effusions?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Alabama Birmingham

Rosai-Dorfman disease is the most tricky one of the top 3 histiocytosis (ECD, LCH, and RDD). It can behave as benign or as an aggressive disease. Given the rarity of the disease, there are no great prospective studies to guide optimal treatments. First-line treatment includes prednisone or other imm...

Do you rebiopsy grade 1-2 follicular lymphoma if SUV is high by PET?

How would you treat a locally recurrent triple negative breast cancer after achieving CR a year earlier to neoadjuvant ddAC-T, BCS and WBRT?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Iowa Holden Comprehensive Cancer Center

I would recommend staging work up to rule out distant metastases for this patient with high-risk TNBC before committing this patient to local therapy.Isolated Loco-regional recurrences (ILRR) are associated with a high risk of developing distant metastases and early recurrence (< 24 months, as in th...

Are there any preferred chemotherapy regimens for Stage IV NUT carcinoma?

5
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Huntsman Cancer Institute, University of Utah

We have a current stage IV NUT carcinoma patient. With permission, I am paraphrasing my discussions with Drs. Christopher French and Dr. Geoffrey Shapiro from Dana Farber Cancer Institute. There is no "standard" first-line chemotherapy regimen. However, in fit patients, the current recommendation a...

How would you approach adjuvant treatment of a locally advanced metaplastic breast cancer with squamous differentiation?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Indiana University School of Medicine

Hopefully, this patient has not yet gone to surgery, although the question suggests this is adjuvant therapy. Metaplastic breast cancer is typically relatively chemoresistant (although I have also had several patients with pCR to standard chemotherapy), with a high risk of hematogenous metastatic sp...

How would you approach the treatment of borderline resectable pancreatic adenocarcinoma in an elderly patient (>80 years old) with a poor performance status who is not a surgical candidate?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · NYU Langone Health System

First, I would recommend making sure that the patient had a surgical evaluation that included a multidisciplinary team with experience in pancreatic surgeries, if possible, including a discussion of whether other medical conditions can be treated to enable a potential surgery.If after this assessmen...